"Beyond triple Therapy: Is dupilumab a cost-effective option for COPD with type 2 inflammation?". Buendia JA, Manrique Acevedo LF, Celis Preciado C. Respir Med 2025;247:108254.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Buendia JA, Manrique Acevedo LF, Celis Preciado C. "Beyond triple Therapy: Is dupilumab a cost-effective option for COPD with type 2 inflammation?". Respir Med 2025;247:108254.
PMID: 40669730